{"id":"NCT00381303","sponsor":"Tibotec, Inc","briefTitle":"GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.","officialTitle":"GRACE: An Open-label, Multicenter Trial to Compare the Efficacy, Safety, and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race, When Administered in Combination With an Individually Optimized Background Regimen Over a 48-week Treatment Period.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-11","primaryCompletion":"2008-11","completion":"2008-12","firstPosted":"2006-09-27","resultsPosted":"2010-10-19","lastUpdate":"2014-04-21"},"enrollment":429,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV","Infectious"],"interventions":[{"type":"DRUG","name":"darunavir","otherNames":[]},{"type":"DRUG","name":"ritonavir","otherNames":[]}],"arms":[{"label":"001","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate any differences in the effectiveness, safety, and tolerability of PREZISTA (darunavir; DRV) 600 mg, administered with ritonavir (RTV) 100 mg twice a day on virologic response (defined as a viral load (VL) of \\< 50 copies/mL) over a 48-week treatment period in HIV-positive women and men. Additional antiretroviral (ARV) agents will also be administered and will be chosen by the Investigator based on resistance testing and prior treatment history (referred to as the Optimized Background Regimen (OBR)).","primaryOutcome":{"measure":"Number of Viral Load (VL) < 50 HIV-1 RNA Copies/mL (Time to Loss of Virologic Response[TLOVR]) Subjects by Sex","timeFrame":"Week 48","effectByArm":[{"arm":"Female","deltaMin":146,"sd":null},{"arm":"Male","deltaMin":83,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.30"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":46,"countries":["United States","Canada","Puerto Rico"]},"refs":{"pmids":["24396625","23092052","20855799"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":47,"n":287},"commonTop":["Nausea","Diarrhoea","Vomiting","Upper Respiratory Tract Infection","Cough"]}}